Call 800-580-9104 to speak with an alcohol or drug abuse counselor.

Who Answers?

Cancer Immunotherapy Shows Long-Term Promise In Lung Cancer

New, long-term results from a clinical trial presented today at the 1st European Lung Cancer Conference jointly organized by the European Society for Medical Oncology (ESMO) and the International Association of the Study of Lung Cancer (IASLC) show that MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic), an immune-boosting treatment for lung cancer patients, reduces the risk of relapse after surgery — to the same extent as chemotherapy but without the side-effects of chemotherapy.

Prof. Johan Vansteenkiste from University Hospital Gasthuisberg in Belgium described the results after 44-months follow-up from a double-blind, placebo-controlled trial in 182 patients with non-small-cell lung cancer — the most common form of the disease.

After complete surgical resection of the tumor, patients were randomly assigned to receive either placebo injections or injections of MAGE-A3 ASCI administered over 27 months (five given at three-week intervals followed by eight given once every three months).

MAGE-A3 is a tumor-specific antigen, expressed in 35-50% of non-small-cell lung cancer, but not on normal cells.

“The aim is to help the body immune system to recognize the MAGE-A3 antigen and therefore eliminate the cancer cells that express MAGE-A3,” explains Prof. Vansteenkiste. “In other words, it is a kind of treatment method that makes the body immune system specifically attack the lung cancer cells.”

After 44 months, 69 of 182 patients had experienced a recurrence of their cancer, including 57 deaths. Those given the MAGE-A3 injections had longer on average before their cancer recurred, were less likely to have any recurrence, and were less likely to die.

“Surgical resection is the standard treatment for patients with early stage lung cancer, but after complete resection about 50% will relapse and die from their cancer,” says Prof. Vansteenkiste. “Postoperative chemotherapy is able to improve cure rates, but is sometimes poorly tolerated by patients recovering from thoracic surgery. In addition, not all patients are fit to receive chemotherapy. This is why the signal from this phase II randomized study is important: the reduction in risk of postoperative cancer relapse is similar to the one obtained with postoperative chemotherapy, while the side-effects of this new strategy are minimal compared to chemotherapy.”

Most patients only experience mild reactions at the injection site and fever within 24 hours of the injection, he explained. “Therefore, it is suitable for long-term maintenance treatment and for most patients, including older patients or patients in weak physical condition after surgery, allowing them to live a normal life whilst on cancer treatment.” A large Phase III trial of the therapy, named MAGRIT, is now underway.

source: http://www.esmo.org/

More Treatment & Detox Articles

5 Ways Parents Can Prevent Teenage Drinking

Teenage drinking is such a health risk that pediatricians are now being told to screen all teenagers—and even sixth graders—for alcohol use. That new policy from the American Academy of Pediatrics can be a powerful tool for parents to help their children avoid trouble with alcohol. But first, parents need to learn to give teenagers….

Dangers of Underage Drinking

There is nothing positive about underage drinking. Teenagers sometimes get behind the wheel and drive under the influence which is a big issue. According to studies by the National Crime Prevention Council, automobile crashes related to underage drinking are the leading cause of death for teens. Approximately 36% of traffic deaths of 15- to 20-year-olds….

‘I have to walk forward to keep where I am’

Every day starts at step one. I am powerless over alcohol. With alcohol my life is unmanageable. For 23 years, Randy has begun his day with the first step of Alcoholics Anonymous’ 12 Step Program. “I always know I am one moment and one drink away from where I was,” Randy said. Randy took his….

Program to Improve Opioid Dependance Treatment

Reckitt Benckiser Pharmaceuticals has launched Here to Help, an unique patient support program designed to improve outcomes for people in opioid dependence treatment with SUBOXONE (buprenorphine HCl/naloxone HCl dihydrate [2 mg/0.5 mg and 8 mg/2 mg]) C-III Sublingual Tablets. By focusing on coaching and education of patients and caregivers, Here to Help is designed to….

Prescription Drug Needs Post Drug Treatment

If you or a loved one is recovering from a drug or alcohol addiction, the need to take prescription medications for an illness or injury can be both dangerous and scary. You don’t want to become addicted to drugs again and yet you know that you need to take the medication. How can you take….